A. Marinelli Andreoli

Pharmacokinetics and Pharmacodynamics of Insulin Glargine Given in the Evening as Compared With in the Morning in Type 2 Diabetes

P. Lucidi, F. Porcellati, P. Candeloro, 2014, Diabetes Care.

Different insulin concentrations in resuspended vs. unsuspended NPH insulin: Practical aspects of subcutaneous injection in patients with diabetes.

P. Lucidi, F. Porcellati, P. Candeloro, 2017, Diabetes & metabolism.

Pharmacokinetics and Pharmacodynamics of NPH Insulin in Type 1 Diabetes: The Importance of Appropriate Resuspension Before Subcutaneous Injection

P. Lucidi, F. Porcellati, P. Candeloro, 2015, Diabetes Care.

GREATER SUPPRESSION OF GLUCAGON, LIPOLYSIS AND KETOGENESIS WITH INSULIN GLARGINE U300 AS COMPARED TO GLARGINE U100 IN TYPE 1 DIABETES MELLITUS.

P. Lucidi, F. Porcellati, P. Candeloro, 2020, Diabetes technology & therapeutics.

Differential Effects of Adiposity on Pharmacodynamics of Basal Insulins NPH, Glargine, and Detemir in Type 2 Diabetes Mellitus

P. Lucidi, P. Rossetti, F. Porcellati, 2011, Diabetes Care.

Pharmacokinetics, Pharmacodynamics, and Modulation of Hepatic Glucose Production With Insulin Glargine U300 and Glargine U100 at Steady State With Individualized Clinical Doses in Type 1 Diabetes

P. Lucidi, F. Porcellati, P. Candeloro, 2018, Diabetes Care.